1. Introduction {#s0005}
===============

Treatment with combination antiretroviral therapy (ART) has increased the lifespans of persons infected with the human immunodeficiency virus (HIV) ([@bb0005], [@bb0130]); however, immune activation and chronic inflammation have been shown to persist in spite of suppressed viral replication ([@bb0050], [@bb0030], [@bb0090], [@bb0110]). Several soluble markers of immune activation and inflammation, including interleukin-6 (IL-6) ([@bb0090], [@bb0200], [@bb0120]), high-sensitivity C-reactive protein (hsCRP), and tumor necrosis factor α receptor I (sTNFR-I) ([@bb0090], [@bb0225], [@bb0095]) are associated with all-cause mortality ([@bb0095] and [@bb0105]) and deaths related to cardiovascular disease (CVD) ([@bb0035]) in HIV-infected individuals ([@bb0225]). Soluble markers of monocyte and macrophage activation (sCD14 or sCD163) are also associated with mortality ([@bb0090] and [@bb0200]), coronary calcium levels ([@bb0120]), and unstable coronary plaques ([@bb0020]) in this population. Comparing the levels of immune activation and inflammation after the initiation of different ART regimens can provide additional information about the effectiveness of the regimens beyond virologic suppression.

Antiretroviral therapy regimens most commonly include two nucleoside reverse transcription inhibitors (NRTIs) and a third drug from a different class. Tenofovir disoproxil fumarate (TDF) ([@bb0150], CID = 6,398,764) is a potent and well-tolerated NRTI recommended by all major treatment guidelines ([@bb0170], [@bb0085], [@bb0040]), but is also associated with greater nephrotoxicity ([@bb0075], [@bb0070], [@bb0180]) and bone mineral density loss ([@bb0220], [@bb0215], [@bb0125]) than other nucleoside or nucleotide reverse transcriptase inhibitors. TDF is a prodrug that is metabolized to tenofovir (TFV), which is diphosphorylated intracellularly to its active metabolite, TFV diphosphate (TFV-DP). Higher circulating plasma TFV levels have been associated with the renal and bone effects of TDF ([@bb0245]).

Tenofovir alafenamide (TAF) ([@bb0155], CID = 9,574,768) is a prodrug of TFV that is more stable in plasma, allowing for a ten-fold reduction in dose and resulting in a 91% reduction in plasma TFV while achieving a four-fold increase in intracellular levels of TFV-DP ([@bb0210]).

A single tablet co-formulation of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) demonstrated high efficacy and improved renal and bone safety across multiple populations in Phase 3 trials: treatment-naïve adults and adolescents, and in adults switching from TDF-based regimens with or without chronic kidney disease ([@bb0210], [@bb0130], [@bb0185], [@bb0055]). It is approved by the [@bb0240] and European Medicines Agency for treatment of naïve and stably suppressed patients age 12 and older and is a recommended initial regimen in U.S. Department of Health and Human Services guidelines ([@bb0235]).

Here, in this randomized, selected substudy of a treatment naïve adult trial (GS-US-292-0104 \[[@bb0210]\]), we compare the effects of E/C/F/TAF versus E/C/F/TDF, referred to as the TAF and TDF groups, respectively, on biomarkers of systemic (IL-6, hsCRP, sTNFR-I) and vascular (lipoprotein-associated phospholipase A~2~ \[Lp-PLA~2~\]) inflammation, coagulation (D-dimer), and soluble markers of myeloid cell activation (sCD14 and sCD163) from baseline through 48 weeks of treatment. In this exploratory analysis, we hypothesized that changes in markers of immune activation would be similar between the groups, as participants in both arms were treated with a potent, integrase-based regimen, and because there were no differences in plasma virologic suppression between the TAF and TDF arms in the parent study. Several potential contributors to chronic immune activation in ART-treated HIV infection have been identified, however, including: microbial translocation and dysbiosis, co-infections, elevations in pro-inflammatory lipid levels, and low level HIV-1 replication in tissue sites that may not be captured by measurement of HIV-1 levels in plasma ([@bb0115]). The differential effects of TDF and TAF on these other drivers of immune activation are also currently not known. As new ART compounds are identified, their effects on indices of immune activation and inflammation that have been linked to morbidity and mortality ([@bb0050], [@bb0115]) will need to be assessed.

2. Materials and Methods {#s0010}
========================

2.1. Study Design {#s0015}
-----------------

This is a substudy (*n* = 200) of a randomized, double-blinded, active-controlled, non-inferiority trial of treatment-naïve adults initiating TAF vs TDF (GS-US-292-0104, *N* = 867, [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0005} number [NCT01780506](ctgov:NCT01780506){#ir0010}) ([@bb0210]). We randomly selected 100 participants from each arm, stratifying by baseline CD4 + and HIV-1 RNA, age, sex, and geography, and excluded participants with known cardiovascular disease or statin use at baseline or during study. This study was conducted in accordance with the Declaration of Helsinki. Central or site-specific institutional review boards or ethics committees reviewed and approved the protocol. All participants provided consent for use of storage samples for future research purposes.

2.2. Measurement of Plasma Biomarkers {#s0020}
-------------------------------------

Plasma levels of immune activation and inflammation were measured in the Funderburg Lab (Ohio State University, Columbus, OH) using commercially available enzyme-linked immunosorbent assay (ELISA) kits. Plasma samples were thawed at 4 °C overnight and analyzed in batch. The concentrations of sCD14, IL-6, hsCRP, sCD163, and TNFR-I (R&D Systems; Minneapolis MN), D-dimer (Asserachrom D-DI immunoassay, Diagnostica Stago, Asnieres France), and Lp-PLA~2~ (PLAC test ELISA kit, Diadexus Inc.; San Francisco CA) were measured using protocols provided by the manufacturers. The inter- and intra-assay variability among these assays ranged between 3.9 and 11.2% and 3.4--9.8%, respectively.

2.3. Statistical Analyses {#s0025}
-------------------------

We summarized baseline levels and percent changes from baseline at post-baseline visits, compared between treatment groups using Wilcoxon Rank Sum, and tested percent changes from baseline at post-baseline visits within treatment groups and overall using Wilcoxon Signed Rank tests. We performed an additional comparison between the two baseline HIV-1 RNA categories by Wilcoxon rank sum test. For the two markers (Lp-PLA~2~ and hsCRP) with accepted clinical cutoffs associated with increased cardiovascular risk (\< 200 or ≥ 200 ng per mL for Lp-PLA~2~, ([@bb0165], [@bb0100], [@bb0240]) \< 3000 or ≥ 3000 ng per mL for hsCRP ([@bb0190])), we used McNemar\'s test to compare if the proportion of participants within each paired categorical data was different at baseline and at post-baseline visits. We also stratified by baseline HIV-1 RNA category (≤ 100,000 vs \> 100,000 copies per mL) to test for differences in the percent changes in any biomarkers between treatment arms. To test equivalence between arms in terms of biomarker change from baseline to week 48, two one-sided tests (TOST) were used, and 90% confidence intervals (CI) were constructed for ratios of biomarker percent change between the two arms, with baseline clinical characteristics, demographics, and other biomarkers at baseline adjusted or not adjusted. To account for correlations among biomarkers, multivariate multiple regression (MMR) was fitted for biomarker percent change from baseline to week 48 against treatment arms, with baseline clinical characteristics, demographics, and baseline biomarkers adjusted. All seven biomarkers collectively were then compared between arms using Wilks\'s lambda test. The machine learning algorithm Random Forest was used to assess biomarkers\' ability to differentiate treatment arms using a receiver operating characteristic (ROC) curve and variable importance analysis.

3. Results {#s0030}
==========

Of the 200 participants selected for this substudy, 194 had evaluable samples (TAF: *n* = 98; TDF: *n* = 96). Baseline demographic and clinical information is provided in [Table 1](#t0005){ref-type="table"}. Median baseline age, CD4 + cell count, and viral load for the subpopulation were similar to those for the parent study. A total of 19% (37 of 194 participants) were women, 44% (85 of 194) were non-white, and 28% (55 of 194) were smokers; the median age was 33 years. The only significant differences between groups were in body mass index (median, TAF: 24 kg per m^2^, TDF: 25 kg per m^2^; *p* = 0.043) and percentage of smokers (TAF: 35% \[34 of 98\], TDF: 22% \[21 of 96\]; *p* = 0.043). Participants had a median CD4 + cell count of 405 cells per μL and a median level of viremia of 4.7 log~10~ copies per mL; 25% had viral load \> 100,000 copies per mL.

Mean increases in CD4 cell counts were similar between groups at week 48 (TAF: 240 cells per μL, TDF: 238 cells per μL; *p* = 0.98). Consistent with the parent study, we found similar declines in viremia between arms. A greater proportion of those receiving the TAF-containing regimen had undetectable viremia (\< 50 copies per mL of HIV-1 RNA, Missing = Failure Analysis) at week 2 compared with those receiving TDF (34% \[33 of 98\] versus 23% \[22 of 96\]; *p* = 0.046), but this difference was not maintained through 48 weeks. From week 16 through week 48, \> 95% of participants in both arms had undetectable levels of HIV-1. There were increases from baseline at week 48 in total cholesterol (TC) (TAF: 20 mg per dL; TDF: 12 mg per dL; *p* = 0.004), low density lipoprotein (LDL) (TAF: 12 mg per dL; TDF: 3 mg per dL; *p* = 0.006), high density lipoprotein (HDL) (TAF: 5 mg per dL; TDF: 3 mg per dL; *p* = 0.045), TC:HDL ratio (TAF: 0.1, TDF: 0.2; *p* = 0.97), and triglycerides (TAF: 16 mg per dL, TDF: 10 mg per dL; *p* = 0.90) ([Fig. 1](#f0005){ref-type="fig"}).

Baseline levels of biomarkers of immune activation and inflammation were similar by treatment arm, and there were no differences between treatment groups at weeks 12, 24, or 48 (*p* \> 0.05, Supplementary [Table 1](#t0005){ref-type="table"}) for any of the markers, except for IL-6 at week 12 only (median, TAF: 1.4 pg per mL, TDF: 1.1 pg per mL; *p* = 0.012). In both arms, biomarkers of systemic inflammation declined after ART initiation, with statistically significant declines (as percentage change) from baseline by week 12 for D-dimer, sCD163, and sTNFR-1 and for IL-6 by week 24 ([Fig. 2](#f0010){ref-type="fig"}, Supplementary Table 1). We did not observe a statistically significant decrease in hsCRP in either arm by 48 weeks of ART; there was a trend toward decline in sCD14 (*p* = 0.061). At baseline, for participants in both arms combined, the median Lp-PLA~2~ level was \< 200 ng per mL (median \[Q1, Q3\] 196 \[159, 23\] ng per mL), indicating a low risk of cardiovascular event ([@bb0165], [@bb0100], [@bb0240]). The proportion of participants with Lp-LA2 levels \< 200 ng per mL did not change through week 48 (*p* = 0.250) (Supplementary Table 2). At baseline, the overall median hsCRP level was \< 3000 mg per L, also indicating a low risk for a cardiovascular event ([@bb0190]). The proportion of participants with hsCRP levels \< 3000 mg per L similarly did not change through week 48 (*p* = 0.586). Stratifying by baseline HIV-1 RNA category (≤ 100,000 vs \> 100,000 copies per mL), we also did not find significant differences in the percent changes in any biomarkers between the TAF and TDF arms at any time point. For participants in each arm and overall, we generally observed a statistically greater decline in biomarkers for those with higher baseline HIV-1 RNA (\> 100,000 copies per mL) compared with those with lower baseline HIV-1 RNA (≤ 100,000 copies per mL) (Supplementary Table 3). Compared with those for participants with lower baseline viral load, the declines in D-dimer, sCD14, sCD163, and sTNF-R1 were greater for those with higher viral load at baseline at all timepoints; in IL-6 at weeks 24 and 48; and in hsCRP at week 24. We saw increases in Lp-PLA~2~ in the lower baseline viral load group at week 24.

Since there was no difference between the TAF and TDF arms, we evaluated equivalence between the TAF and TDF arms using multiple statistical approaches. First, we assessed equivalence using the two one-sided test (TOST) ([Fig. 3](#f0015){ref-type="fig"}). All biomarker percent changes were equivalent between arms by TOST except hsCRP. The 90% CI of ratios between two arms were within 80% to 125% for all biomarkers, except for hsCRP, which had wider 90% CI with a ratio of 105.3% (90%CI: 80.7%, 137.4%) when not adjusting for other covariates and 100.8% (90%CI: 76.4%, 132.9%) when adjusting for other covariates. We then confirmed the equivalence finding by TOST by using MMR and Wilks\'s lambda test (*p* = 0.997); biomarker percent changes at week 48 were equivalent between arms. Lastly, we used Random Forest (ROC area under curve \[AUC\]), which demonstrated that there was no differentiation between arms in any biomarker percent changes at week 48 ([Fig. 4](#f0020){ref-type="fig"}). The AUC of ROC curve was 0.49 (95%CI: 0.41, 0.57), and variable importance scores were \< 0.5% for all biomarkers.

4. Discussion {#s0035}
=============

Initiation of ART has increased dramatically the expected lifespans of persons living with HIV; yet in spite of reducing viral replication below the limits of detection by standard clinical assays, residual chronic immune activation and systemic inflammation often persist ([@bb0030], [@bb0090], and [@bb0115], [@bb0065], [@bb0045]). As new ART drugs become available, clinicians and patients may decide whether they wish to change the current ART regimen. The decision to switch a virologically suppressive regimen has been determined by patient tolerability, pill burden/dosing frequency, and drug-associated toxicities ([@bb0170]). As newer ART drugs become available with improved tolerability, clinicians and patients may wish to consider the role or association of residual immune activation and chronic inflammation and the association with non-AIDS related (e.g. non-infectious, cardiovascular) morbidity and mortality. Several contributors to chronic immune activation in ART-treated HIV infection have been identified, including microbial translocation, dysbiosis, coinfections, and low level viral replication ([@bb0115]). In this substudy, we compared the effects of 48 weeks of TAF versus TDF on markers of inflammation and immune activation that have been associated with all-cause mortality and cardiovascular event risk in this population ([@bb0090], [@bb0200], [@bb0120], [@bb0095], [@bb0105], [@bb0035], [@bb0020]). We hypothesized that the declines in immune activation would be comparable given equivalent virologic suppression in both arms. We report that after initiation of ART regimens containing either TAF or TDF, there were equivalent declines in biomarkers of monocyte activation and systemic inflammation over 48 weeks of treatment. As expected given the results from the parent study ([@bb0210]), substudy participants in both arms had rapid and sustained virologic suppression and significant increases in CD4 + cell counts. Within both arms, we report significant reductions in levels of IL-6, D-dimer, sCD163, and sTNFR-1 by week 24; these decreases were sustained through week 48. Median levels of sCD14, a monocyte activation marker, declined from baseline by 5.7% by week 48, which trended toward significance (*p* = 0.061). Somewhat surprisingly, we did not find statistically significant reductions in plasma levels of Lp-PLA~2~, a marker of vascular inflammation, at any time during the study. In fact, the proportion of participants with Lp-PLA~2~ (as measured by mass in our study) \< 200 ng per mL (the threshold for predicting cardiovascular events) remained unchanged through week 48 (*p* = 0.250). Of note, in a subanalysis of the JUPITER study in non-HIV infected individuals, among participants allocated to placebo, increasing quartiles of Lp-PLA~2~ activity (*p* = 0.04) but not Lp-PLA~2~ mass (*p* = 0.92) were associated with incident cardiovascular events after adjustment for LDL-C and conventional risk factors ([@bb0195]).

Based on the less than expected changes in sCD14 and Lp-PLA~2~ in both arms, in spite of virologic control, we wanted to investigate changes in lipid levels as a potential contributor to immune activation in this study. At weeks 24 and 48, there were small, statistically significant differences in increases in total cholesterol, LDL cholesterol, and HDL cholesterol for participants receiving TAF compared with those receiving TDF, but no difference in the TC:HDL ratio, which is associated with cardiovascular risk ([@bb0030], [@bb0250], [@bb0025], [@bb0060]). These findings are consistent with what has been seen in other TAF vs TDF studies ([@bb0210], [@bb0135], [@bb0255]) and are thought to be due to greater plasma TFV concentrations with TDF ([@bb0255], [@bb0230], [@bb0205], [@bb0140], [@bb0010], [@bb0175]). Traditional lipid panels may underestimate cardiovascular risk in HIV-infected individuals, ([@bb0145]) and there is growing appreciation that pro-inflammatory lipids may contribute to immune activation in persons infected with HIV, including oxidized LDL, as levels of oxidized LDL have been associated with levels of sCD14 in this population ([@bb0260], [@bb0080], [@bb0160]). The basic lipid assessment performed in this substudy may not be sufficient to entirely capture changes in pro-inflammatory lipid subspecies and their contribution to persistent immune activation. In addition to the lack of change in the TC: HDL ratio, it is also reassuring, however, that there were no differences between the TAF arm and the TDF arm in Lp-PLA~2~ or hsCRP, indicating that the modest increases in lipid levels in the TAF arm are likely not associated with increased cardiovascular risk.

Limitations of the present analysis include that it was a post-hoc substudy and may not have been appropriately powered to be able to see differences between arms, and that we did not adjust for multiple comparisons conducted. Another potential limitation of this study is the lack of single copy assay measurement of viral replication or measurement of HIV-1 replication in the tissues. Based on the higher intracellular concentrations of TFV associated with TAF, a more sensitive assay may have identified a differential decline in viral replication between the two arms; however, as both TAF and TDF were given with the highly effective boosted integrase regimens, it may not be possible to have seen this effect, even with a more sensitive assay. Indeed, when using an HIV-1 RNA lower limit of detection of \< 20 copies/mL at Week 48, no differences in the rate of viral suppression was seen between the two treatment arms ([@bb0210]). Also, as there are likely several contributors of immune activation and inflammation in ART-treated HIV infection, the plasma based assays we used to measure changes in immune activation indices may not be sensitive enough to detect subtle changes associated with modulation of any of these potential drivers of activation, including viral replication on single cell level. We report that after initiation of ART, regimens containing either TAF or TDF have equivalent reductions in markers of immune activation and inflammation in persons living with HIV. This is a key finding, as HIV-infected individuals are living longer, experiencing a greater cumulative exposure to ART, and are at a greater risk for treatment-associated toxicities. Treatment with a TAF-based therapy, compared to one containing TDF, has been associated with smaller declines in bone mineral density and decreased renal toxicity ([@bb0210]).

5. Conclusions {#s0040}
==============

Treatment with TAF, compared to TDF, yields equivalent improvements in immune health and inflammatory indices, with decreased bone and renal toxicity. Beyond durable suppression of HIV viremia, treatment strategies should seek to optimize viral suppression while reducing residual immune activation and inflammation, which are increasingly associated with the clinical events that now contribute substantially to the long-term morbidity and mortality of persons living with HIV on lifelong therapy.
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![Fasting lipids at baseline and week 48.\
*P*-values calculated using Wilcoxon rank-sum test for treatment comparison of change from baseline at Week 48.](gr1){#f0005}

![Percent changes in markers of inflammation and immune activation.\
Plasma samples were thawed and levels of A) soluble CD14 (sCD14), soluble CD163 (sCD163), B) C reactive protein (hsCRP), tumor necrosis factor receptor type 1 (TNFr-I), D-dimer, interleukin-6 (IL-6) and C) lipoprotein-associated phospholipase A2 (Lp-PLA2) were measured by ELISA. Differences in percent changes were assessed by Wilcoxon rank-sum test.](gr2){#f0010}

![Changes in levels of biomarkers: equivalence by two one-sided test.\
Using TOST, equivalence is established at α significance level if a (1--2α) ∗ 100% confidence interval (CI) for the ratio of treatment 1/treatment 2 is contained within a range around 100%, such as (80%--125%).](gr3){#f0015}

![Changes in levels of biomarkers: equivalence by Random Forest.\
Machine learning algorithm Random Forest with receiver operating characteristic (ROC) curve and variable importance was used to assess the biomarkers\' ability to differentiate between arms ([@bb0015]).\
BL, baseline; Hb, hemoglobin; CLcr, creatinine clearance.](gr4){#f0020}

###### 

Demographics and baseline clinical characteristics.

Table 1

                                                 TAF (*n* = 98)      TDF (*n* = 96)      Total (*n* = 194)   *p*-Value
  ---------------------------------------------- ------------------- ------------------- ------------------- -----------
  Age, median (IQR)                              34 (26, 41)         32 (27, 41)         33 (26, 41)         0.95
  Female, n (%)                                  21 (21)             16 (17)             37 (19)             0.40
  Black, n (%)                                   19 (19)             13 (14)             32 (16)             0.27
  BMI, median (IQR)                              24 (22, 27)         25 (22, 29)         24 (22, 28)         **0.043**
  US region, n (%)                               48 (49)             54 (56)             102 (53)            0.31
  CD4 count, cells per μL, median (IQR)          402 (254, 591)      405 (297, 521)      405 (274, 560)      0.82
  CD4 \< 200 cells per μL, n (%)                 16 (16)             13 (14)             29 (15)             
  HIV RNA, log~10~ copies per mL, median (IQR)   4.7 (4.1, 5.0)      4.7 (4.3, 4.9)      4.7 (4.2, 5.0)      0.78
  HIV RNA \< 100,000 copies per mL, n (%)        72 (74)             74 (77)             146 (75)            0.27
  Smoker, n (%)                                  34 (35)             21 (22)             55 (28)             **0.043**
  Total cholesterol, mg per dL, median (IQR)     163 (146, 184)      167 (149,195)       166 (147, 187)      0.17
  LDL, mg per dL, median (IQR)                   106 (88,122)        109 (91, 129)       107 (89, 127)       0.20
  HDL, mg per dL, median (IQR)                   46 (35, 54)         46 (37, 54)         46 (36, 54)         0.67
  Triglycerides, mg per dL, median (IQR)         106 (77, 153)       108 (82, 137)       107 (80, 145)       0.70
  TC:HDL ratio, median (IQR)                     3.8 (3.1, 4.3)      3.6 (3.2, 4.4)      3.6 (3.2, 4.3)      0.97
  eGFR by Cockcroft-Gault, median (IQR)          120 (103, 135)      116 (102, 139)      118 (103, 137)      0.95
  Hemoglobin, g per dL, median (IQR)             14.3 (13.2, 15.3)   14.6 (13.5, 15.2)   14.4 (13.2, 15.2)   0.39
  Diabetes mellitus, n (%)                       3 (3)               3 (3)               6 (3)               0.98
  Hypertension, n (%)                            10 (10)             16 (17)             26 (13)             0.19
  Hyperlipidemia, n (%)                          2 (2)               4 (4)               6 (3)               0.39

Bold lettering denotes a p-value less than 0.05.
